Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients.

Abstract

The present clinical data demonstrate the importance of basal tumoral-reduced folates for the achievement of optimal efficacy of FU-based treatment. They may have implications for the identification of patients resistant to FU chemotherapy and for a better understanding and management of FU modulation by folinic acid (FA).